The CSL Limited (ASX: CSL) share price is trading lower on Tuesday afternoon.
At the time of writing, the biotherapeutics giant’s shares are down slightly to $298.06.
Whatâs going on with the CSL share price?
The CSL share price is trading slightly lower today amid broad market weakness.
This weakness appears to have offset the release of a positive announcement relating to CSLâs product portfolio.
According to the release, the European Commission has granted conditional marketing authorisation for HEMGENIX (etranacogene dezaparvovec).
This is for the first gene therapy option for the treatment of severe and moderately severe Hemophilia B (congenital Factor IX deficiency) in adults without a history of Factor IX inhibitors by a single infusion.
This follows approval by the US Food and Drug Administration for HEMGENIX for the same indications in November.
But wait thereâs moreâ¦
Another positive that CSL has announced relates to the garadacimab or CSL312 therapy, which is currently undergoing phase 3 clinical trials.
Garadacimab is CSLâs investigational monoclonal antibody that is being developed as a long-term prophylactic treatment for patients with hereditary angioedema (HAE).
The good news is that results from the trial, the first to investigate targeting activated Factor XII (FXIIa) to prevent HAE attacks, showed that once-monthly subcutaneous injections significantly reduced the attack rate compared to placebo.
Based on these results, CSL will proceed with regulatory submissions to global health authorities later this calendar year for full approval of garadacimab.
This could be a very big positive for CSL’s future. Goldman Sachs has recently suggested that garadacimab could end up being a âpipeline in a productâ thanks to multiple end use possibilities. It commented:
CSL312 is a humanised anti-factor XIIa monoclonal antibody in development for multiple indications including as a subcutaneous therapy for HAE, with the potential for administration every 4 weeks (vs. every 2-3 days for Haegarda). Given its early position in the coagulation cascade, there is also potential application in various other disorders (including fibrosis, cardiovascular and inflammatory indications).
The post CSL share price lower despite portfolio update appeared first on The Motley Fool Australia.
Should you invest $1,000 in CSL right now?
Before you consider CSL , you’ll want to hear this.
Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and CSL wasn’t one of them.
The online investing service heâs run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.
See The 5 Stocks
*Returns as of February 1 2023
(function() {
function setButtonColorDefaults(param, property, defaultValue) {
if( !param || !param.includes(‘#’)) {
var button = document.getElementsByClassName(“pitch-snippet”)[0].getElementsByClassName(“pitch-button”)[0];
button.style[property] = defaultValue;
}
}
setButtonColorDefaults(“#0095C8”, ‘background’, ‘#5FA85D’);
setButtonColorDefaults(“#0095C8”, ‘border-color’, ‘#43A24A’);
setButtonColorDefaults(“#fff”, ‘color’, ‘#fff’);
})()
More reading
- ‘Long-term value’: Expert names 2 ASX 200 shares to buy for years to come
- Top brokers name 3 ASX shares to buy next week
- Brokers name 3 ASX shares to buy now
- Top broker says CSL shares will hit $350, buy now
- Top brokers name 3 ASX shares to buy today
Motley Fool contributor James Mickleboro has positions in CSL. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended CSL. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
from The Motley Fool Australia https://ift.tt/KCDvBzb
Stock Pick 